Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.47 |
| ▸ | GSK3B | P49841 | 17/20 | 0.47 |
| ▸ | WNT1 | P04628 | 16/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25260395 | 0.95 | DYRK1A (0.45) | DYRK1AGSK3BWNT1TTKMAPK8 | |
| SCHEMBL25262270 | 0.83 | KIFC1 (0.46) | — | |
| SCHEMBL25295369 | 0.79 | KIFC1 (0.48) | — | |
| SCHEMBL25814262 | 0.78 | KIFC1 (0.50) | DYRK1AGSK3BWNT1 | |
| SCHEMBL25814123 | 0.78 | HDAC3 (0.36) | — | |
| SCHEMBL25813252 | 0.76 | DYRK1A (0.42) | DYRK1AGSK3BWNT1TTKMAPK8 | |
| SCHEMBL25813410 | 0.76 | KIFC1 (0.40) | DYRK1AGSK3BWNT1TTK | |
| SCHEMBL31607765 | 0.75 | DYRK1A (0.45) | DYRK1AGSK3BWNT1TTK | |
| SCHEMBL27103542 | 0.75 | DYRK1A (0.45) | DYRK1AGSK3BWNT1TTK | |
| SCHEMBL25301296 | 0.75 | KIFC1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | DYRK1A 3206/4885GSK3B 1241/4885WNT1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.